Real-world experience of adalimumab in the treatment of hidradenitis suppurativa - 10/04/21
Doi : 10.1016/j.jaad.2020.12.012
Hasan Khosravi, MD a, ⁎ 
, Alyce M. Anderson, MD, PhD a, Caroline Kettering, BS b, Alicia Mizes, BS b, Timothy Patton, DO a
, Alyce M. Anderson, MD, PhD a, Caroline Kettering, BS b, Alicia Mizes, BS b, Timothy Patton, DO a a Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania
b University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
∗Correspondence to: Hasan Khosravi, MD, 3601 Fifth Ave, 5th Floor, Pittsburgh, PA 152133601 Fifth Ave, 5th FloorPittsburghPA15213
| Funding sources: None. |
|
| IRB approval status: Reviewed and approved by the University of Pittsburgh Institutional Review Board (IRB STUDY19100133). |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 5
P. 1406-1409 - mai 2021 Retour au numéro
Article précédent
- Serum cytokine levels in patients with hidradenitis suppurativa vary with race
- Cather McKay, Drew Kuraitis, Andrea Murina
- Seroconversion of severe acute respiratory syndrome coronavirus 2–infected patients on immunosuppression: A retrospective analysis
- Jeffrey S. Smith, Jordan T. Said, Scott A. Elman, Claire E.P. Smith, Joseph F. Merola
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?